05-09-05

12

10/701.990

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

	•
Filing Date	November 4, 2003
First Named Inventor	Marc K. HELLERSTEIN
Art Unit	1645
Examiner Name	Not Yet Assigned
Attorney Docket Number	416272005200

	ENCLOSURES (Check all that apply)					
Fee Transm	nittal Form	Drawing(s)		After Allowance Communication to TC		
Fee A	attached	Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences		
Amendmen	t/Reply	Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)		
After	Final	Petition to Convert to a Provisional Application		Proprietary Information		
Affida	vits/declaration(s)	Power of Attorney, Revocation Change of Correspondence		Status Letter		
Extension of	of Time Request	Terminal Disclaimer	3.1	X Other Enclosure(s) (please Identify below):		
Express Ab	andonment Request	Request for Refund	15 S	 PTO/SB/08a/b (8 pages) 104 Cited References 		
	Disclosure Statement ntal, 3 pages)	CD, Number of CD(s)		Return Receipt Postcard		
Certified Co	opy of Priority s)	Landscape Table on	CD			
Reply to Mincomplete	ssing Parts/ Application	Remarks				
Reply 37 CF	to Missing Parts under FR 1.52 or 1.53					
	SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm Name	MORRISON & FOERSTER LLP (Customer No. 20872)					
Signature	Signature Michael Ploud					
Printed name	Michael R. Ward					
Date	May 5 , 2005		Reg. No.	38,651		

I hereby certify that this correspondence is to in an envelope addressed to: Commissione	ing deposited with the U.S. Postal Service as Express Mail, Airbill N for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the dat	o. EV731514217US, e shown below.
Dated: May 5 , 2005	gnature: (Laura Tsang)	

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV731514217US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below

ated: May 5, 2005

Patent Docket No. 416272005200

B03-021

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Marc K. HELLERSTEIN

Serial No.: 10/701,990

Filing Date: November 4, 2003

DEUTERATED GLUCOSE OR FAT

TOLERANCE TESTS FOR HIGH-THROUGHPUT MEASUREMENT OF THE METABOLISM OF SUGARS OR

FATTY ACIDS IN THE BODY

Examiner: Not Yet Assigned

Group Art Unit: 1645

SUPPLEMENTAL INFORMATION DISCLOSURE **STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

	This Supplemental Information Disclosure Statement is submitted:
	With the application; accordingly, no fee or separate requirements are required.
	Before the mailing of a first Office Action after the filing of a Request for Continued
	Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97
	(e)(1) has been provided.
\boxtimes	Within three months of the application filing date or before mailing of a first Office
	Action on the merits; accordingly, no fee or separate requirements are required.
	However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
	After receipt of a first Office Action on the merits but before mailing of a final Office Action
	or Notice of Allowance.
	A fee is required. A check in the amount of is enclosed.
	A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to
	this submission in duplicate.
	A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is
	believed to be due.
	After mailing of a final Office Action or Notice of Allowance, but before payment of the
	issue fee.
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the
	amount of is enclosed.
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal
	form (PTO/SB/17 is attached to this submission in duplicate.)
	Applicants would appreciate the Examiner initialing and returning the Form

PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 416272005200.

Dated: May 4, 2005

Respectfully submitted,

Michael R. Ward

Registration No.: 38,651

MORRISON & FOERSTER LLP

425 Market Street

San Francisco, California 94105-2482

(415) 268-6237



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 8

Complete if Known				
Application Number	10/701,990			
Filing Date	November 4, 2003			
First Named Inventor	Marc K. HELLERSTEIN			
Art Unit	1645			
Examiner Name	Not Yet Assigned			
Attorney Docket Number	416272005200			

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	1.	US-4,332,784	06-01-1982	Smith et al.				
	2.	US-5,439,803	08-08-1995	Ross et al.				
	3.	US-5,961,470	10-05-1999	Wagner et al.				
	4.	US-6,653,076	11-25-2003	Franza, Jr. et al.				
	5.	US-2003/0148533	08-07-2003	Malloy et al.				
	6.	US-2003/0180710	09-25-2003	Lee et al.				
	7.	US-2003/0180800	09-25-2003	Lee et al.				
	8.	US-2003/0228259-A1	12-11-2003	Hellerstein				
	9.	US-2004/0081994	04-29-2004	Hellerstein				
	10.	US-2004/0091943	05-13-2004	Schneider				
	11.	US-2004/0152994	08-05-2004	Meier-Augenstein				
	12.	US-2004/0253647	12-16-2004	Mathews et al.				
	13.	US-2005/0019251-A1	01-27-2005	Hellerstein				
	14.	US-2005/0053992-A1	03-10-2005	Hellerstein				
	15.	US-10/519,121	FD 09-15-2003	Hellerstein				
	16.	US-10/523,250	FD 01-26-2005	Hellerstein				
	17.	US-10/526,860	FD 09-04-2003	Hellerstein				
	18.	US-10/872,280	FD 06-17-2004	Hellerstein				
	19.	US-10/963,967	FD 10-12-2004	Hellerstein				
	20.	US-10/997,323	FD 11-23-2004	Hellerstein				
	21.	US-11/064,197	FD 02-22-2005	Hellerstein				
	22.	US-11/078,083	FD 03-11-2005	Hellerstein				
	23.	US-11/094,387	FD 03-29-2005	Hellerstein				

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages				
inibais	NO.	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	T⁵			
	24.	WO-90/11371	10-04-1990	Anticancer, Inc.					
	25.	WO-93/25705	12-23-1993	Barranco					
	26.	WO-03/061479-A1	07/31/2003	Hellerstein					
	27.	WO-03/068919-A2	08/21/2003	Hellerstein					
	28.	WO-03/087314-A2	10/23/2003	Hellerstein					
	29.	WO-04/003493-A2	01/08/2004	Hellerstein					
1	30.	WO-04/011426-A2	02/05/2004	Hellerstein					
	31.	WO-04/021863-A2	03/18/2004	Hellerstein		Г			
	32.	WO-04/024941-A2	03/25/2004	Hellerstein		Г			

Examiner	·	Date	
Signature		Considered	
- (4044040			

Substitute for form 1449/PTO			<u> </u>	Complete if Known		
				Application Number	10/701,990	
11	NFORMATION	I DI	SCLOSURE	Filing Date	November 4, 2003	
S	STATEMENT BY APPLICANT			First Named Inventor	Marc K. HELLERSTEIN	
				Art Unit	1645	
(Use as many sheets as necessary)			necessary)	Examiner Name	Not Yet Assigned	
Sheet	2	of	8	Attorney Docket Number	416272005200	

33.	WO-04/025270-A2	03/25/2004	Hellerstein	
34.	WO-04/042360-A2	05/21/2004	Hellerstein	
35.	WO-05/009597-A2	02/03/2005	Hellerstein	٦
36.	WO-05/015155-A2	02/17/2005	Hellerstein	\neg
37.	WO-05/033652-A2	04/14/2005	Hellerstein	

^{*}EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	38.	International Search Report mailed on June 29, 2004, for PCT	
		application no. PCT/US03/04183 filed on February 12, 2003, 4 pages	
	39.	International Search Report mailed July 8, 2004, for PCT patent	
		application no. PCT/US03/27623 filed on September 4, 2003, 4 pages	
	40.	International Search Report mailed August 18, 2004, for PCT	
		application PCT/US03/23340, filed July 25, 2003, 2004: 4 pages	
	41.	International Search Report mailed on August 18, 2004, for PCT	
		application PCT/US03/29526, filed September 16, 2003, 3 pages	
	42.	International Search Report mailed on August 20, 2004, for PCT	
		application no. PCT/US03/10554 filed on April 4, 2003, 4 pages	
	43.	International Search Report mailed on January 19, 2005, for PCT	
		application no. PCT/US03/29361 filed on September 15, 2003, 4	
		pages	
	44.	International Search Report mailed on March 25, 2005, for PCT	
		application no. PCT/US04/39722 filed on November 24, 2004, 3 pages	١.
	45.	International Search Report mailed on April 4, 2005, for PCT	
		application no. PCT//US04/21063 filed on June 29, 2004, 2 pages	
	46.	"New Diagnostic Technique Could Help Treat AIDS," Agence France-	
		Presse, Dow Jones News/Retrieval, Feb. 17, 1998, pp. 1-2.	
	47.	ADAMI, H.O. et al. (1995) "The Aetiology and Pathogenesis of Human	
		Breast Cancer" Mutation Research 333: 29-35	1
	48.	ANDERSON, R.W. et al. (1998) "Direct HIV Cytopathicity Cannot	
		Account for CD4 Decline in AIDS in the Presence of Homeostasis: A	
		Worst-Case Dynamic Analysis" J. AIDS and Human Retrovirology	
		17:245-252	
	49.	ASHER, E. et al. (1995) "Evaluation of Cell Death in EBV-Transformed	

Examiner		Date	
Signature		Considered	

Sub	stitute for form 1449/PTO			Complete if Known		
				Application Number 10/701,990		
II.	IFORMATION	l DI	SCLOSURE	Filing Date	November 4, 2003	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Marc K. HELLERSTEIN	
				Art Unit	1645	
	(Use as many she	ets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet 3 of 8		Attorney Docket Number	416272005200			

F	Г	Lymphocytes Using Agarose Gel Electrophoresis, Light Microscopy	
		and Electron Microscopy" Leukemia and Lymphoma 19:107-119	
	50.	BACH, Simon P. et al. (2000) "Stem Cells: The Intestinal Stem as a	
	50.	Paradigm" Carcinogenesis 21(3): 469-476	
	51.	BICKENBACH, J.R. (1981) "Identification and Behavior of Label-	
	31.		
	52.	Retaining Cells in Oral Mucosa and Skin" J Dent Res 1611-1620	
	52.	BIER, D.M. (1997) "Stable Isotopes in Biosciences, Their Measurement and Models for Amino Acid Metabolism" <i>Eur J Pediatr</i>	
1			
	E2	156 [Supp. 1]: S2-S8	
	53.	BLACK, G.E. et al. (January 2001) "Labeling DNA with Stable	
1		Isotopes: Economical and Practical Considerations," <i>BioTechniques</i>	
	F 4	30:134-140	
1	54.	BLAU, K. and HALKET, J. eds. (1993) Handbook of Derivatives for	
 	r.r	Chromatography, 2nd Edition, John Wiley & Sons Ltd., England	
	55.	BRAVO, Elena et al. (1994) "Decreased Hepatic Uptake and	
ŀ		Processing of High Density Lipoprotein Unesterified Cholesterol and	
-		Cholesteryl Ester with Age in the Rat" J. Biochem. 116: 1088-1095	
	56.	BROWN, Alan S. et al (1998) "Treating Patients with Documented	
		Atherosclerosis to National Cholesterol Education Program-	
		Recommended Low-Density-Lipoprotein Cholesterol Goals with	
		Atorvastatin, Fluvastatin, Lovastatin and Simvastatin" J. Am. Coll.	
		Cardiol. 32: 665-672	
	57.	BUCY, R.P. et al. (1998) "Analysis of Lymph Node Biopsies in HIV	
1		Infected Patients Before and After HAART" Abstract, 5th Conference	
ļ	ļ	on Retroviruses and Opportunistic Infections, Session 66 519:177	
ļ	58.	CALDWELL, K.A. et al. (1993) "Quantification of Peptide Isotopomer	
		Abundances and Determination of Protein (sic) Turnover Rates by	
		Using Mass Isotopomer Distribution Analysis" Abstract, 41st Annual	
	ļ	Amer. Society Mass Spectrometry on Mass Spectrometry, p. 331a.	
	59.	CASSELLA, C.R. et al. (1997) "Mechanisms of Lymphocyte Killing by	
		HIV" Current Opinion in Hematology 4:24-31	
1	60.	CESAR, D. et al. (1998) "Direct Measurement of CD4+ and CD8+ T	
		Cell Proliferation Rates in Vivo in AIDS Patients Using a Stable	
	į	Isotope-Mass Spectrometric Technique" Abstract, 5th Conference on	
		Retroviruses and Opportunistic Infections, Chicago Illinois	
	61.	COHEN, A. et al. (1983) "Purine and Pyrimidine Metabolism in Human	
<u> </u>		T Lymhocytes," J. Biol. Chem. 258(20):12334-12340	
	62.	COHEN, J. (1998) "Failure Isn't What It Used to BeBut Neither is	
		Success" Science 279:1133-1134	

Examiner	Date
Signature	Considered
-6.4044240	

Sub	estitute for form 1449/PTO			Complete if Known		
				Application Number	10/701,990	
IN.	NFORMATION	l Di	SCLOSURE	Filing Date	November 4, 2003	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Marc K. HELLERSTEIN	
				Art Unit	1645	
	(Use as many she	eets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	Sheet 4 of 8		Attomey Docket Number	416272005200		

63.	CONNERS, M. et al. (1997) "HIV Infection Induces Changes in CD4+ T-Cell Phenotype and Depletions Within the CD4+ T-Cell Repertoire that are not Immediately Restored by Antiviral or Immune-Based Therapies" <i>Nature Medicine</i> 3(5):533-540	
64.	CRAIN, P.F. (1990) "Preparation and Enzymatic Hydrolysis of DNA and RNA for Mass Spectrometry," <i>Meth. Enz.</i> 193:782-790	
65.	DEEKS, S. et al. (1998) "Viral Load and CD4+ T Cell Changes in Patients Failing Potent Protease Inhibitor Therapy" Abstract, 5th Conference on Retroviruses and Opportunistic Infections, Session 53, 419:158	
66.	DIMITROV, D.S. et al. (1995) Scientific Correspondence, <i>Nature</i> 375:194-195	
67.	GOROCHOV, G. et al. (1998) "Perturbation of CD4+ and CD8+ T-Cell Repertoires During Progression to AIDS and Regulation of the CD4+ Repertoire During Antiviral Therapy," <i>Nature Medicine</i> 4(2):215-221	
68.	GOZ, Barry (1978) "The Effects of Incorporation of 5-Halogenated Deoxyuridines into DNA of Eukaryotic Cells" Macological Reviews 29, (4): 249-272	
69.	GRATZNER, H.G. (1982) "Monoclonal Antibody to 5-Broma-and 5-lododeoxyuridine: A New Reagent for Detection of DNA Replication" Science 218:474-475	
70.	GYGI, Steven et al. (2000) "Using Mass Spectrometry for Quantitative Proteomics" <i>Proteomics: A Trends Guide:</i> 31-36	
71.	HANSEN, Andrew P. et al. (1992) "A Practical Method for Uniform Isotopic Labeling of Recombinant Proteins in Mammalian Cells" <i>Biochemistry</i> 31 (51): 12713-12718.	
72.	HELLERSTEIN, M.K. et al. (1997) "T Cell Turnover in HIV-1 Disease," <i>Immunity</i> 7:583-589 (Nov. 1997).	
73.	HO, D.D. et al. (1995) "Rapid Turnover of Plasma Virions and CD4 Lymphocytes in HIV-1 Infection," <i>Nature</i> 373:123-126	
74.	HSIEH, Elaine A. et al. (2004) "Dynamics of Keratinocytes in Vivo Using 2H2O Labeling: A Sensitive Marker of Epidermal Proliferation State," J Invest Dermatol, 123: 530-536	
75.	JAMES, J.S. (1998) "Clinical Implications of Virological Failure: Interview with Steven Deeks, M.D., San Francisco General Hospital," AIDS Treatment News, 289:6-7	
76.	LIPKIN, M. (1987) "Proliferation and Differentiation of Normal and Diseased Gastrointestinal Cells" In Physiology of the Gastrointestinal Tract , L.R. Johnson ed., Raven Press, New York, pp. 255-284	

Examiner	Date
I Characters I	15
Signature	Considered
. 1011010	~

Sub	stitute for form 1449/PTO		, <u> </u>	Complete if Known		
				Application Number	10/701,990	
II.	IFORMATION	I DI	SCLOSURE	Filing Date	November 4, 2003	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Marc K. HELLERSTEIN	
				Art Unit	1645	
	(Use as many she	eets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet 5 of 8		Attorney Docket Number	416272005200			

	LIDION Marker at al (4000) NO II D. C. C. C. C. C. C.	
77.	LIPKIN, Martin et al. (1963) "Cell Proliferation Kinetics in the	
	Gastrointestinal Tract of Man. I. Cell Renewal in Colon and Rectum"	
	Journal of Clinical Investigations 42(6):767-776	
78.	MAENTAUSTA, O. et al. (1979) "Radioimmunoassay of Conjugated	
	Cholic Acid, Chenodeoxycholic Acid, and Deoxycholic Acid from	
	Human Serum, with Use of 125I-Labeled Ligands" Clin. Chem. 25(2):	
	264-268	
79.	MARGOLICK, J.B. et al. (1995) "Failure of T-cell Homeostasis	
	Preceding AIDS in HIV-1 Infection," Nature Medicine, 1(7):674-680	
80.	MCCLOSKEY, J.A. (1990) "Electronionization Mass Spectra of	
	Trimethylsilyl Derivatives of Nucleosides," Meth. Enz. 193:825-841	.
81.	MCCUNE, J.M. (1997) "Thymic Function in HIV-1 Disease," Seminars	
	in Immunology 9:397-404	
82.	MCLEAN, A.R. et al. (1995) "In Vivo Estimates of Division and Death	
	Rates of Human T Lymphocytes," Proc. Natl. Acad. Sci USA 92:3707-	
	3711	
83.	MEIER, P.R. et al. (March 1981) "Rates of Protein Synthesis and	
	Turnover in Fetal Life," Am J Physiol., 240(3):E320-E324	
84.	MELLORS, J.W. et al. (1995) "Quantitation of HIV-1 RNA in Plasma	
	Predicts Outcome after Seroconversion," Ann. Intern. Med. 122:573-	
	579	
85.	MELLORS, J.W. et al. (1996) "Prognosis in HIV-1 Infection Predicted	
	by the Quantity of Virus in Plasma," Science, 272:1167-70	
86.	MESSMER, Bradley T. et al. (Feb. 10, 2005) "In Vivo Measurements	
	Document the Dynamic Cellular Kinetics of Chronic Lymphocytic	}
	Leukemia B Cells," J. Clin. Invest. doi:10.1172/JCI200523409	
87.	MICHIE, C.A. et al. (1992) "Lifespan of Human Lymphocyte Subsets	
	Defined by CD45 Isoforms," Nature 360:264-265	
88.	MORRIS, Rebecca J. et al. (1997) "Evidence that a Slowly Cyling	
	Subpopulation of Adult Murine Epidermal Cells Retains Carcinogen"	
	Cancer Research 46: 3061-3066	
89.	MORRIS, Rebecca J. et al. (1997) "Evidence that Cutaneous	
	Carcinogen-initiated Epithelial Cells from Mice are Quiescent Rather	
	than Actively Cyling" Cancer Research 57:3436-3443	
90.	MOSIER, D.E. (1995) "CD4.sup.+ Cell Turnover," <i>Nature</i> 375:193-194	
91.	MURALI-KRISHNA, K. et al. (1998) "Counting Antigen-Specific CD8 T	\vdash
	Cells: A Reevaluation of Bystander Activation during Viral Infection,"	
	Immunity 8:177-187	
92.	NEESE, R. A. et al. (Nov. 2002) "Measurement in vivo of Proliferation	
192.	INCLUE, N. A. et al. (NOV. 2002) Weasurement III VIVO OF FIORIERATION	L

Examiner	Date
	1 1
Signature	Considered I

Sub	stitute for form 1449/PTO			Complete if Known		
				Application Number	10/701,990	
II.	IFORMATION	I DI	SCLOSURE	Filing Date	November 4, 2003	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Marc K. HELLERSTEIN	
				Art Unit	1645	
	(Use as many she	eets as 	necessary)	Examiner Name	Not Yet Assigned	
Sheet 6 of		8	Attorney Docket Number	416272005200		

<u></u>		Rates of Slow Turnover Cells by 2H2O Labeling of the Deoxyribose	
		Moiety of DNA," PNAS, 99(24): 15345-15350	
	93.	ONG, Shao-En et al. (2002) "Stable Isotope Labeling by Amino Acids	-
	J	in Cell Culture, SILAC, as a Simple and Accurate Approach to	
		Expression Proteomics" <i>Molecular and Cellular Proteomics</i> 1: 376-386	
	94.	OYAIZU, N. et al. (1995) "Role of Apoptosis in HIV Disease	
	•	Pathogenesis," J. of Clinical Immunology 15(5):217-231	
	95.	PALMER, L.D. et al. (1997) "Telomere Length, Telomerase Activity,	
		and Replicative Potential in HIV Infection: Analysis of CD4+ and CD8+	
		T Cells from HIV-discordant Monozygotic Twins," J. Experimental	
		Medicine 185(7):1381-1386	
	96.	PAPAGEORGOPOULOS, C. et al.(1993) "Toward the Measurement of	
		Protein Synthesis by Mass Isotopomer Distribution Analysis	
		(MIDA):Resolution of Isotopomers in a [d.sub.3]-Leucine Enriched	
		Synthetic Oligopeptide Using Electrospray/Quadrupole Mass	ļ
		Spectrometry (ESI/MS)," Abstract, Federation of American Societies	
		for Experimental Biology 1022:A177	
	97.	PARK, S. S., et al. (1997) "Measurement of Small Intestinal Cell	
		Turnover with [6,6, 2H2] Glucose," Berkeley Scientific, Abstract	
		1(2):41-43	
}	98.	PAŠA-TOLIC, Ljiljana et al. (1999) "High Throughput Proteome-Wide	
	ļ	Precision Measurements of Protein expression Using Mass	
		Spectrometry" J. Am. Chem. Soc. 121: 7949-7950	
	99.	PATTON, G.M. et al. (July 1979) "Measurements of Fatty Acid	
		Synthesis by Incorporation of Deuterium from Deuterated Water,"	
	100	Biochemistry, 18(14):3186-3188	
	100.	PERELSON, A.S. et al.(1996) "HIV-1 Dynamics in Vivo: Virion	
		Clearance Rate, Infected Cell Life-Span, and Viral Generation Time,"	
-	404	Science 271:1582-1586	ļ
	101.	PERELSON, A.S. et al.(1997) "Decay Characteristics of HIV-1-	
	}	Infected Compartments During Combination Therapy," Nature	
<u> </u>	102	387:188-191	<u> </u>
	102.	POZHARISSKI, K.M. et al. (1980) "Study of Kinetics of Epithelial Cell	
		Populations in Normal Tissues of the Rat's Intestines and in Carcinogenesis." Exp. Path., Bd. 18:387-406	
	103.		_
1	103.	Federation Proceedings 37(1):9-14	
	104	REICHARD, P. (1988) "Interactions Between Deoxyribonucleotide and	-
	107.	DNA Synthesis," Ann. Rev. Biochem. 57:349-374	
L	<u> </u>	Dia Cymhodio, Aim. Nov. Diodiom. 01.043-014	

Examiner	Date	
Signature	Considered	
	100/10/00/00	

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/701,990	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	November 4, 2003	
				First Named Inventor	Marc K. HELLERSTEIN	
				Art Unit	1645	
				Examiner Name	Not Yet Assigned	
Sheet	7	of	8	Attorney Docket Number	416272005200	

	ROCHA, B. et al. (1990) "Accumulation of Bromodeoxyuridine- Labelled Cells in Central and Peripheral Lymphoid Organs: Minimal Estimates of Production and Turnover Rates of Mature Lymphocytes" Eur. J. Immunol. 20:1697-1708	
	RODA, Aldo et al. (1980) "Results with Six 'Kit' Radioimmunoassays for Primary Bile Acids in Human Serum Intercompared" Clin. Chem. 26(12): 1677-1682	
107.	ROEDERER, M. (July 1995) "T-Dell Dynamics of Immunodeficiency," Nature Medicine 1(7):621-622	
108.	SAWADA, S. et al. (1995) "Comparison of Autoradiography, Liquid Scintillation Counting and Immunoenzymatic Staining of 5-bromo-2'-deoxyuridine for Measurement of Unscheduled DNA Synthesis and Replicative DNA Synthesis in Rat Liver," <i>Mutation Research</i> 344:109-116	
109.	SCALISE, K. (Feb. 11-17, 1998) "Tracking T-Cells in AIDS Patients: A Safe Reliable Method of Measuring Human Cell Generation Rates," <i>Berkeleyan,</i> p. 3.	
110.	SHEVCHENKO, Andrej et al. (1997) "Rapid 'de Novo' Peptide Sequencing by a Combination of Nanoelectrospray, Isotopic Labeling and a Quadrupole/Time-of-flight Mass Spectrometer" Rapid Commun. Mass Spectrom. 11: 1015-1024	
111.	SHIGENAGA, M.K. et al. (1994) "Assays of Oxidative DNA Damage Biomarkers 8-Oxo-2'-deoxyguanosine and 8-Oxoguanine in Nuclear DNA and Biological Fluids by High-Performance Liquid Chromatography with Electrochemical Detection," <i>Methods in Enzymology</i> 234:16-33	
112.	SMITH, et al. (1983) "The Phosphogluconate Odixative Pathway," in Principles of Biochemistry, 7th edition, McGraw-Hill Book Company, pp. 417-423.	
113.	SPRENT, J. et al. (1995) "CD4+ Cell Turnover," Nature 375:194	
	SUNTER, J.P. et al. (1978) "Cell Population Kinetics in the Epithelium of the Colon of the Male Rat." Virchows Archiv. B Cell Path. 26: 275-287	
	TINT, G.S. et al. (1974) "Transformation of 5α-cholest-7-en-3β-ol to Cholesterol and Cholestanol in Cerebrotendinous Xanthomatosis" Journal of Lipid Research 15: 256-262	
116.	TRABER, P.G. et al. (1991) "Isolation of Intestinal Epithelial Cells for the Study of Differential Gene Expression Along the Crypt-Villus Axis," <i>Am. J. Physiol.</i> 260:G895-G903	

Examiner	Date	
Signature	Considered	
£ 4044040	 	

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/701,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	November 4, 2003
				First Named Inventor	Marc K. HELLERSTEIN
				Art Unit	1645
(Use as many sheets as necessary)			necessary)	Examiner Name	Not Yet Assigned
Sheet	8	of	8	Attorney Docket Number	416272005200

117.	VEENSTRA, Timothy D. et al. (2000) "Proteome Analysis Using Selective Incorporation of Isotopically Labeled Amino Acids" <i>J. Am. Soc. Mass. Spectrom.</i> 11: 78-82	
118.	WADKE, M. et al. (July 1973) "Fatty Acid Synthesis by Liver Perfused with Deuterated and Tritiated Water," Biochemistry., 12(14):2619-2624	
119.	WAIN-HOBSON, S. (1995) "Virological Mayhem," Nature 373:102	
120.	WALDEMAN, F.M. et al. (1991) "A Comparison Between Bromodeoxyuridine and 3 H Thymidine Labeling in Human Breast Tumors," <i>Modern Path.</i> 4(6):718-722	
121.	WEI, X et al. (1995) "Viral Dynamics in Human Immunodeficiency Virus Type 1 Infection," <i>Nature</i> 373:117-122	
122.	WOLFE, R. (1990) "Isotopic Measurement of Glucose and Lactate Kinetics," <i>Ann. Med.</i> 22:163-170	
123.	WOLTHERS et al. (1998) "Rapid CD4+ T-Cell Turnover in HIV-1 Infection: a Paradigm Revisited," <i>Immunol. Today</i> 19(1):44-48	
124.	WOLTHERS, K.C. et al. (1996) "T Cell Telomere Length in HIV-1 Infection: No Evidence for Increased CD4+ T Cell Turnover," <i>Science</i> 274:1543-1547	
125.	WOOD, H.G. et al. (1963) "Estimation of Pathways of Carbohydrate Metabolism," <i>Biochemische Zeitschrift</i> 338:809-847	
126.	ZHANG, Z-Q. et al. (Feb. 1998) "Kinetics of CD4+ T Cell Repopulation of Lymphoid Tissues after Treatment of HIV-1 Infection," <i>Proc. Natl. Acad. Sci. USA</i> 95:1154-1159	
127.	ZILVERSMIT, D.B. et al. (1943) "On the Calculation of `Turnover Time` and `Turnover Rate` from Experiments Involving the Use of Labeling Agents," <i>J. of General Physiology</i> 26(3):325-331	

^{*}EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	 Considered	
£ 4044040		

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.